Endocrinology Research and Practice
Orijinal Araştırma

Immunohistochemical and Clinical Assessment of Low-Risk Thyroid Tumors

1.

Division of Internal Medicine, Department of Endocrinology and Metabolism, Ankara University Faculty of Medicine, Ankara, Turkey

2.

Department of Endocrinology and Metabolism, Güven Hospital, Ankara, Turkey

3.

Endocrinology Clinic, Leyla Medical Center, Baku, Azerbaijan

4.

Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Endocrinol Res Pract 2023; 27: 199-204
DOI: 10.5152/erp.2023.23238
Okunma: 1173 İndirilme: 330 Online Yayın Tarihi: 05 Ekim 2023

Objective: Differential diagnosis and prognosis of low-risk follicular cell-derived thyroid neoplasms have been conflicting. We aimed to evaluate immunohistochemical features and prognosis of tumors in “well-differentiated tumor of uncertain malignant potential” and “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” categories.

Methods: Fifty-two low-risk thyroid tumors which were classified as well-differentiated tumor of uncertain malignant potential (n=23) and noninvasive follicular thyroid neoplasm with papillary-like nuclear features (n=29) with a follow-up of at least 60 months were included. Galectin-3, HBME-1, CK19, and CD56 expressions were evaluated. The control group included benign nodules (n=53), conventional papillary thyroid carcinomas (n=37), and encapsulated follicular variant papillary thyroid carcinomas (n=60).

Results: During a median 84 months follow-up period, none of the patients experienced a recurrence of tumor. Expression of HBME-1 in low-risk tumors was significantly frequent than benign and infrequent than malignant tumors (P=.001 and P < .001, respectively). The frequency of galectin-3 positivity was similar between low-risk and malignant tumors (P=.805) and significantly higher in low-risk tumors when compared to benign nodules (P < .001). Expression of CK19 in low-risk tumors was significantly frequent than benign nodules and infrequent than malignant tumors (P=.01 and P=.001, respectively). The expression profile of CD56 was similar in benign nodules and low-risk tumors (P=.361). Total loss of CD56 in tumor was the most specific marker of malignancy (100%). Positive staining of HMBE-1 was the most sensitive marker (89.7%) for predicting malignancy.

Conclusion: Low-risk thyroid tumors had immunohistochemical features overlapping with both benign and malignant thyroid tumors and had a benign course of disease during a long follow-up period.

Cite this article as: Aydoğan Bİ, Hasanov R, Yüksel S, Sevim S, Dizbay Sak S, Güllü S. Immunohistochemical and clinical assessment of low-risk thyroid tumors. Endocrinol Res Pract. 2023;27(4):199-204.

Ekler
ENGLISH
EISSN 2822-6135